drugset / Trial / NCT00190489
A Trial of Doxorubicin/Cyclophosphamide (AC), Docetaxel (D), and Alternating AC and D for Metastatic Breast Cancer
Phase 3
Completed
450 enrolled
Japan Clinical Oncology Group
Ministry of Health, Labour and Welfare, Japan · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
To investigate the clinical benefits of Docetaxel or alternating AC-Docetaxel in comparison with standard AC for metastatic breast cancer
Timeline
- Start
- 1999-01
- Primary completion
- 2006-05
- Completion
- 2006-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CPA | Unknown | 500 mg/m2 | — |
| Subject | Docetaxel | Small molecule | 60 mg/m2 | — |
| Subject | Doxorubicin | Other / unclassified | 40 mg/m2 | — |